-- ユニシンク（UNI.TO）は金曜日、第2四半期の純利益と売上高が増加したと発表した。 2026年3月31日までの3ヶ月間において、同社の純利益は220万ドル（1株当たり0.11ドル）となり、前年同期の10万ドル（1株当たり損益分岐点）から増加した。四半期調整後EBITDAは、前年同期の320万ドルから470万ドルに増加した。 売上高は、前年同期の2,450万ドルから2,870万ドルに増加した。これは主に、当四半期中に出荷を開始した既発表の新規事業によるものだと同社は述べている。 また、同社は当四半期中に、UGLおよびPeerlessの両事業部門で年間820万ドルの新規事業を獲得した。新規事業の大部分は米国での獲得である。 同社の株価は木曜日、トロント証券取引所で1.5%上昇し、2.1ドルで取引を終えた。
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.
Research
B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target
Unicycive Therapeutics (UNCY) has an average rating of buy and mean price target of $41.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $7.62, Change: $-0.04, Percent Change: -0.59%
$UNCY